Омела белая Viscum album Mistletoe
жүктеу/скачать 2.26 Mb.
|
- Бұл бет үшін навигация:
- Conflict of Interests
- Authors Contribution
- Article information
5. ConclusionThe combination of mistletoe and gemcitabine was well tolerated and treatment compliance was high. The MTD was gemcitabine 1380  mg/m2 weekly on day one and eight of a 3-week cycle combined with mistletoe 250 mg daily. Gemcitabine pharmacokinetics were not affected by mistletoe. The lack of febrile neutropenia even at higher gemcitabine doses is noteworthy. The formation of ML antibodies is common. A consistent effect of the study regimen on the serum levels of selected cytokines could not be demonstrated. Clinical response of the combination appeared to be similar to single agent gemcitabine reported previously.
Conflict of InterestsAll authors were contacted, and the possibility of conflict of interests was explored. None of the authors listed reported any conflict of interests regarding the content of this paper or investigational agents used for the research reported therein. Authors' ContributionDawn B. Wallerstedt, Timothy S. Sannes, and Jamie Stagl contributed to data collection and interpretation and paper writing. All other authors also contributed to the design and funding of the study. AcknowledgmentsThe authors would like to acknowledge the help and advice of Drs. Agnes Nguyenpho, FDA; Maria Merino, Laboratory of Pathology, NCI; Alex Ling, Diagnostic Imaging Department, Clinical Center, NIH; and Julia T. Arnold, NCCAM. They greatly appreciate the technical assistance of Howard Baldwin, NCCAM, and the support of Drs. Dieter Schlodder and Juergen Schierholz as well as Sabine Rieger from Helixor GmbH. The authors also thank the NIH and NNMC fellows, nurses, pharmacy staff, and all the patients who made it possible to conduct this study. This research was supported, in part, by the Intramural Research Programs of the NIH, NCCAM, and NCI and was done at the Intramural Research Program of the National Center for Complementary and Alternative Medicine, National Institutes of Health. Conclusions drawn and recommendations for future directions made are the opinions of the authors and do not represent the view of the National Center for Complementary and Alternative Medicine, The Department of the Navy, Department of Defense, or the National Cancer Institute. Mistletoe extract (Helixor A) was provided by Helixor GmbH, Rosenfeld, Germany, which also supported the mistletoe lectin analyses.
Article informationEvid Based Complement Alternat Med. 2013; 2013: 964592. Published online Oct 27, 2013. doi: 10.1155/2013/964592 PMCID: PMC3826324 Patrick J. Mansky, 1 , 2 ,* Dawn B. Wallerstedt, 3 Timothy S. Sannes, 4 Jamie Stagl, 5 Laura Lee Johnson, 2 Marc R. Blackman, 6 Jean L. Grem, 7 Sandra M. Swain, 8 and Brian P. Monahan 9 1The Cancer Team at Bellin Health, 1580 Commanche Avenue, Green Bay, WI 54313, USA 2National Center for Complementary and Alternative Medicine, NIH, Bethesda, MD, USA 3Samuelli Institute, Alexandria, VA, USA 4Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA 5University of Miami, Miami, FL, USA 6Research Service (151), Veterans Affairs Medical Center, and Department of Medicine, Georgetown University School of Medicine, Washington, DC, USA 7University of Nebraska Medical Center, Omaha, NE, USA 8Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA 9Department of Medicine, Hematology and Medical Oncology Division, Uniformed Services University of the Health Sciences, Bethesda, MD, USA |